Compare Heron Therapeutics Inc (HRTX) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Southern Copper Corp — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Southern Copper Corp trades at $204.26 (market cap $167.74B). The key difference: Southern Copper Corp is far larger — about 2466.4× Heron Therapeutics Inc's market cap, and Southern Copper Corp pays a 2.21% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Southern Copper Corp for 61 Days on average.
| HRTX | SCCO | |
|---|---|---|
Market Cap | $68.01M | $167.74B |
Volume | 1,891,941 | 853,110 |
Sector | Health | Basic Materials |
52-Week High | $1.49 | $219.70 |
52-Week Low | $0.27 | $120.02 |
Typical Hold Time | 35 Days | 61 Days |
Enterprise Value | $174.75M | $169.03B |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Southern Copper (SCCO) trades at $200.57, down 1.81% on the day, with technical indicators showing a neutral bias. The company demonstrates strong fundamentals with revenue growth from $13.42B in 2025 to projected $15.8B in 2026 and net income margins expanding to 35.87%. Recent earnings have consistently beaten expectations, and the company maintains robust profitability metrics including 50.07% ROE. A stock split and dividend payment are scheduled for August 2026.
SCCO presents a mixed investment case with strong operational performance offset by premium valuations. The stock trades above analyst consensus target of $167.67, suggesting limited near-term upside. Key risks include copper price volatility and competitive pressures, while growth catalysts include Mexican project pipeline development. Analyst sentiment remains divided with only 10.34% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
